HEALEY ALS Platform Trial: Mechanism of Action and Science - ABBV-CLS-7262, Regimen F

Explore the science behind ABBV-CLS-7262, the investigational product being tested in Regimen F of the HEALEY ALS Platform Trial, in this informative 56-minute webinar. Join experts Dr. Merit Cudkowicz and Dr. Sabrina Paganoni from Massachusetts General Hospital, along with regimen co-lead Dr. Senda Ajroud-Driss from Northwestern University and research scientists from Calico Life Sciences as they present the rationale and scientific basis for this potential ALS treatment. Gain insights into the mechanism of action and participate in a Q&A session with the presenters. Learn about the latest developments in ALS research, access additional resources on the Platform Trial Study Drugs webpage, and discover how to stay informed about future webinars and ALS research updates through the ALS Link newsletter. Connect with MGH Neurology on social media platforms for ongoing updates in the field of neurology and ALS research.

HEALEY ALS Platform Trial: Mechanism of Action & Science Webinar: ABBV-CLS-7262, Regimen F